Cg Oncology, INC Schedule 13G passive stakes

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 9.7% of CG Oncology, Inc.'s common stock as of June 30, 2026.

T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 8.0% of CG Oncology Inc.'s common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong have reported a beneficial ownership of 8.3% in CG Oncology, Inc., holding 6,984,808 shares.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in CG Oncology Inc. following an internal realignment.

Wellington Management Group LLP and its affiliates have reported a 7.2% beneficial ownership stake in CG Oncology, Inc. as of September 30, 2025.

The Vanguard Group has reported an increased beneficial ownership of 8.62% in CG Oncology Inc.'s common stock, totaling 6,577,281 shares.

FMR LLC and Abigail P. Johnson have reported a 5.1% beneficial ownership stake in CG Oncology Inc. as of June 30, 2025.

TCG Crossover Fund I, L.P., its general partner TCG Crossover GP I, LLC, and Chen Yu have filed an amended Schedule 13G, disclosing their beneficial ownership in CG Oncology, Inc. has decreased to 4.8% as of March 31, 2025.

Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, and affiliated entities, including Xiangmin Cui, have filed an amended Schedule 13G disclosing a combined passive beneficial ownership of 8.4% in CG Oncology, Inc. as of December 31, 2024.

A group of entities including ORI Healthcare Fund, L.P., ORI Healthcare Fund II, L.P., and their affiliates, along with Ms. Hong Fang Song, have filed an amended Schedule 13G disclosing their passive beneficial ownership in CG Oncology, Inc.